Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jo, Hyoung | - |
dc.contributor.author | Jung, Sang Hoon | - |
dc.contributor.author | Kang, Jun | - |
dc.contributor.author | Yim, Hye Bin | - |
dc.contributor.author | Kang, Kui Dong | - |
dc.date.accessioned | 2024-01-20T08:31:02Z | - |
dc.date.available | 2024-01-20T08:31:02Z | - |
dc.date.created | 2021-09-02 | - |
dc.date.issued | 2014-11-30 | - |
dc.identifier.issn | 1976-6696 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/126091 | - |
dc.description.abstract | Sulodexide is a mixed glycosaminoglycan composed of heparin and dermatan sulfate. In this study, the anti-angiogenic effect of sulodexide was investigated using an oxygen-induced retinopathy (OIR) mouse model. The retinas of sham-injected OIR mice (P17) had a distinctive central area of nonperfusion, and this area was significantly decreased in sulodexide-injected mice. The number of neovascular tufts measured by SWIFT_ NV and mean neovascular lumen number were significantly decreased in sulodexide-injected mice. Hyperbaric oxygen exposure resulted in increased levels of VEGF, MMP-2 and MMP-9, and when mice were treated with sulodexide, a dose-dependent reduction in VEGF, MMP-2 and MMP-9 levels was observed. Our results clearly demonstrate the anti-angiogenic effect of sulodexide and highlight sulodexide as a candidate supplementary substance to be used for the treatment of ocular pathologies that involve neovascularization. | - |
dc.language | English | - |
dc.publisher | KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY | - |
dc.subject | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject | RETRO-ORBITAL INJECTION | - |
dc.subject | DIABETIC-NEPHROPATHY | - |
dc.subject | FACTOR VEGF | - |
dc.subject | RECEPTOR | - |
dc.subject | CELLS | - |
dc.subject | ANGIOGENESIS | - |
dc.subject | PREMATURITY | - |
dc.subject | EXPRESSION | - |
dc.title | Sulodexide inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy | - |
dc.type | Article | - |
dc.identifier.doi | 10.5483/BMBRep.2014.47.11.009 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | BMB REPORTS, v.47, no.11, pp.637 - 642 | - |
dc.citation.title | BMB REPORTS | - |
dc.citation.volume | 47 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 637 | - |
dc.citation.endPage | 642 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.identifier.wosid | 000345347400006 | - |
dc.identifier.scopusid | 2-s2.0-84914814617 | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject.keywordPlus | RETRO-ORBITAL INJECTION | - |
dc.subject.keywordPlus | DIABETIC-NEPHROPATHY | - |
dc.subject.keywordPlus | FACTOR VEGF | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | ANGIOGENESIS | - |
dc.subject.keywordPlus | PREMATURITY | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordAuthor | Angiogenesis | - |
dc.subject.keywordAuthor | MMP | - |
dc.subject.keywordAuthor | Retinopathy | - |
dc.subject.keywordAuthor | Sulodexide | - |
dc.subject.keywordAuthor | VEGF | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.